Legend Biotech
(NASDAQ) LEGN
Legend Biotech Financials at a Glance
Market Cap
$6.20B
Revenue (TTM)
$1.14B
Net Income (TTM)
-$250.18M
EPS (TTM)
-$1.36
P/E Ratio
-24.54
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Price
$33.13
Volume
284,615.208
Open
$33.71
Price
$33.13
Volume
284,615.208
Open
$33.71
Previous Close
$33.38
Daily Range
$32.22 - $33.94
52-Week Range
$16.24 - $45.30
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Price
$33.13
Volume
284,615.208
Open
$33.71
Previous Close
$33.38
Daily Range
$32.22 - $33.94
52-Week Range
$16.24 - $45.30
Estimated Earnings Date
Aug 10, 2026
LEGN News
LEGN: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Legend Biotech
Industry
Biotechnology
Sector
Health CareEmployees
2,900
CEO
Ying Huang, PhD
Website
www.legendbiotech.comHeadquarters
Somerset, NJ 08873, US
LEGN Financials
Key Financial Metrics (TTM)
Gross Margin
55%
Operating Margin
-12%
Net Income Margin
-22%
Return on Equity
-25%
Return on Capital
-12%
Return on Assets
-16%
Earnings Yield
-4.07%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$6.20B
Shares Outstanding
185.74M
Volume
284.62K
Avg. Volume
2.39M
Financials (TTM)
Gross Profit
$620.80M
Operating Income
-$136.50M
EBITDA
-$232.30M
Operating Cash Flow
-$100.47M
Capital Expenditure
-$67.58M
Free Cash Flow
-$168.04M
Cash & ST Invst.
$948.60M
Total Debt
$413.70M
Legend Biotech Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$305.10M
+56.4%
Gross Profit
$129.20M
+4.4%
Gross Margin
42.35%
N/A
Market Cap
$6.20B
N/A
Market Cap/Employee
$2.38M
N/A
Employees
2,600
N/A
Net Income
-$54.30M
+46.2%
EBITDA
-$32.00M
+64.0%
Quarterly Fundamentals
Total Cash
$834.63M
-17.0%
Total Debt
$389.31M
+7.3%
Accounts Receivable
$186.61M
+11.8%
Inventory
$37.10M
+19.9%
Long Term Debt
$112.10M
-68.6%
Short Term Debt
$277.20M
+5090.0%
Return on Assets
-15.67%
N/A
Return on Invested Capital
-12.48%
N/A
Free Cash Flow
-$111.33M
-5.3%
Operating Cash Flow
-$85.35M
+17.7%